[Amplification of protooncogenes and expression of the HER2/neu oncogene in invasive breast cancer].
The protooncogene HER2/neu was analyzed in 27 women with invasive breast cancer and in 26 with benign breast conditions. Gene amplification was found in 3 patients, 1 in stage 3 and 2 in stage 4. In 3 patients in stage 2 overexpression of protein was found. Although amplification of the gene was found to be a significant predictor of clinical outcome (p < 0.05), high expression of the gene did not correlate with prognosis. In women with benign breast conditions there were no alterations of HER2/neu amplification may become a molecular marker in some malignancies. It should be noted that since few tumors show amplification, examination of a small series may not reveal clinical association with these alterations. Therefore, our conclusions require confirmation on a larger scale with long-term clinical follow-up.
Ben-Aharon
U
U
Dept. of Surgery, Kaplan Medical Center, Rehovot.
Gutman
M
M
Shani
E
E
Chatsubi
I
I
Pfefferman
R
R
Shiloh
Y
Y
Tal
M
M
D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D006801:Humans; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases